Source:http://linkedlifedata.com/resource/pubmed/id/16904834
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2006-10-9
|
pubmed:abstractText |
Amyloid beta-protein (Abeta) increases apolipoprotein E (apoE) levels in astrocytes which could alter lipid trafficking. The mechanism for the Abeta-induced increase in apoE levels is not well understood. It is well established that stimulation of beta-adrenergic receptors (betaARs) increases cAMP levels. Elevation of cAMP levels increases apoE abundance. The current study determined if Abeta(1-42) stimulation of cAMP and apoE levels could be inhibited by betaAR antagonists in astrocytes. We demonstrate that Abeta(1-42) but not the reverse protein Abeta(42-1) or Abeta(1-40) stimulated cAMP formation and this stimulation was inhibited by selective betaAR antagonists in mouse primary cortical astrocytes. Abeta(1-42) significantly increased apoE levels which were significantly inhibited by the betaAR selective antagonists with the greatest inhibition observed with the beta(2) antagonist. Separate lines of evidence have suggested that agonist-induced stimulation of betaARs and increases in apoE abundance may serve a neuroprotective role in astrocytes. Our results indicate a potential interaction between betaARs and apoE which may contribute to reducing Abeta(1-42) neurotoxicity.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Amyloid beta-Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins E,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/amyloid beta-protein (1-42)
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0306-4522
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
27
|
pubmed:volume |
142
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
655-60
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:16904834-Adrenergic beta-Antagonists,
pubmed-meshheading:16904834-Amyloid beta-Peptides,
pubmed-meshheading:16904834-Animals,
pubmed-meshheading:16904834-Animals, Newborn,
pubmed-meshheading:16904834-Apolipoproteins E,
pubmed-meshheading:16904834-Astrocytes,
pubmed-meshheading:16904834-Blotting, Western,
pubmed-meshheading:16904834-Cells, Cultured,
pubmed-meshheading:16904834-Cyclic AMP,
pubmed-meshheading:16904834-Drug Interactions,
pubmed-meshheading:16904834-Gene Expression,
pubmed-meshheading:16904834-Immunoenzyme Techniques,
pubmed-meshheading:16904834-Mice,
pubmed-meshheading:16904834-Mice, Inbred C57BL,
pubmed-meshheading:16904834-Peptide Fragments,
pubmed-meshheading:16904834-Time Factors
|
pubmed:year |
2006
|
pubmed:articleTitle |
Amyloid beta-protein1-42 increases cAMP and apolipoprotein E levels which are inhibited by beta1 and beta2-adrenergic receptor antagonists in mouse primary astrocytes.
|
pubmed:affiliation |
Geriatric Research, Education and Clinical Center, VA Medical Center and Department of Pharmacology, University of Minnesota School of Medicine, One Veterans Drive, Minneapolis, MN 55417, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, N.I.H., Extramural
|